PAREXEL Launches Perceptive MyTrials Data-Driven Monitoring
PAREXEL announced the launch of its Perceptive MyTrials Data-Driven Monitoring solution.
PAREXEL announced the launch of its Perceptive MyTrials® Data-Driven Monitoring solution. Developed by PAREXEL Informatics, it is a key component of its Perceptive MyTrials eClinical platform, an integrated suite of applications for managing clinical trials.
Perceptive MyTrials Data-Driven Monitoring an centralized monitoring approach that uses clinical data to guide monitoring activities as an alternative to periodically scheduled monitoring visits. This data can drive decision-making in determining when on-site monitoring visits need to occur and what activities should be undertaken during those visits. Monitoring focused on specific risks offers the potential to enhance patient safety, reduce costs and promote regulatory compliance.
Read the full release here.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
